-transparent.png){kind=logo}
The accumulation of aluminum in bone can cause disabling osteodystrophy in patients with renal failure. Because the chelating agent deferoxamine can mobilize aluminum from tissues, we evaluated the effect of a standard intravenous dose of deferoxamine on plasma aluminum concentrations in 54 patients on hemodialysis. Stainable bone aluminum, bone histologic findings, and bone aluminum content were studied. Baseline plasma aluminum concentrations of greater than 200 micrograms/L were associated with aluminum-related osteodystrophy (specificity, 93%), but concentrations of less than 200 micrograms/L did not exclude the diagnosis (sensitivity, 43%). After administration of deferoxamine, the increase in plasma aluminum concentration was 534 +/- 260 (SD) and 214 +/- 92 micrograms/L in patients with and without aluminum-related bone disease, respectively (p less than 0.001), and correlated with the bone aluminum content (r = 0.64). An increment in plasma aluminum concentration of greater than 200 micrograms/L identified 35 of the 37 patients with aluminum-related osteodystrophy; sensitivity was 94% and specificity, 50%. The deferoxamine infusion test is noninvasive, well tolerated, and of value particularly in excluding the diagnosis of aluminum-related osteodystrophy.
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
January 1988,
Contributions to nephrology,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
January 1989,
Advances in internal medicine,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
August 1986,
ANNA journal,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
December 1986,
Seminars in nephrology,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
May 1993,
Mayo Clinic proceedings,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
February 1991,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
January 2001,
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
July 1987,
The Journal of clinical endocrinology and metabolism,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
February 1986,
Kidney international. Supplement,
D S Milliner, and
H G Nebeker, and
S M Ott, and
D L Andress, and
D J Sherrard, and
A C Alfrey, and
E A Slatopolsky, and
J W Coburn
March 1993,
Zhonghua nei ke za zhi,
